Methods of treating hematological malignancies with nucleoside analog drugs 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2006053252 A2 2006-05-18 [WO200653252]WO2006053252 A3 2006-07-27 [WO200653252] / 2006-05-182006-07-27
申请号/申请日
2005WO-US41037 / 2005-11-14
发明人
GHIAS KULSOOM;MA CHUNGUANG;GANDHI VARSHA;PLATANIAS LEONIDAS C;KRETT NANCY L;ROSEN STEVEN T;
申请人
SOPHERION THERAPEUTICS;
主分类号
IPC分类号
A01N-043/04A61K-031/70A61K-049/00
摘要
(WO200653252) The present invention provides methods of treating hematological malignancies, including multi-drug resistant malignancies, with 8-amino-adenosine and variants thereof.  Also encompassed by the present invention is a method of predicting the response of a patient diagnosed with a hematological malignancy to treatment with a nucleoside analog and a method of screening candidate drugs for efficacy in treating hematological malignancies.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2004US-60626862 2004-11-12
主权利要求
(WO200653252) We claim: 1. A method of treating a subject diagnosed with a hematological malignancy, comprising administering a nucleoside analog drug at a time and dosage sufficient to achieve substantial reduction in phosphorylation of one or more of MKK3, MKK6, ρ38 MAP kinase, ERKl, ERK2, Akt kinase, and downstream signaling molecules thereof. 2. The method of claim 1 , wherein said nucleoside analog drug is 8 -amino-adenosine. 3. The method of claim 1 , wherein said hematological malignancy is leukemia, lymphoma, or myeloma. 4. The method of claim 3, wherein said subject was in remission from said hematological malignancy and relapsed. 5. The method of claim 3, wherein said hematological malignancy is myeloma. 6. The method of claim 5, wherein the myeloma results in an increase in number of plasma cells in bone marrow of said subject. 7. The method of claim 6, wherein said plasma cells are myeloma cells. 8. The method of claim 7, wherein said myeloma cells are multi-drug resistant. 9. The method of claim 5, further comprising assaying Bence-Jones proteins in urine of said subject, wherein a reduction or absence of Bence-Jones proteins is indicative of an effective treatment of said myeloma. 10. The method of claim 9, wherein said reduction of Bence-Jones proteins is at least about a 10% reduction in measured Bence-Jones proteins, at least about a 20% reduction in measured Bence-Jones proteins, at least about a 30% reduction in measured Bence-Jones proteins, at least about a 40% reduction in measured Bence- Jones proteins, at least about a 50% reduction in measured Bence-Jones proteins, at least about a 60% reduction in measured Bence-Jones proteins, at least about a 70% reduction in measured Bence-Jones proteins, at least about an 80% reduction in measured Bence-Jones proteins, at least about a 90% reduction in measured Bence- Jones proteins, at least about a 95% reduction in measured Bence-Jones proteins, or at least about a 99% reduction in measured Bence-Jones proteins. 11. The method of claim 5 , further comprising assaying serum proteins of said subject for M protein, wherein a reduction or absence of M protein is indicative of an effective treatment of myeloma. 12. The method of claim 11, wherein said reduction of M protein is at least about a 10% reduction in measured M protein levels, at least about a 20% reduction in measured M protein levels, at least about a 30% reduction in measured M protein levels, at least about a 40% reduction in measured M protein levels, at least about a 50% reduction in measured M protein levels, at least about a 60% reduction in measured M protein levels, at least about a 70% reduction in measured M protein levels, at least about an 80% reduction in measured M protein levels, at least ab out a 90% reduction in measured M protein levels, at least about a 95% reduction in measured M protein levels, or at least about a 99% reduction in measured M protein levels. 13. The method of claim 11, wherein the absence of M protein is determined by immunofixation. 14. The method of claim 11, wherein said serum proteins are assayed by serum electrophoresis. 15. The method of claim 6, further comprising performing a biopsy on bone marrow of said subject to confirm a reduction in number of plasma cells indicative of an effective treatment of myeloma. 16. The method of claim 15, wherein said biopsy shows at least about a 5% reduction in number of plasma cells, at least about a 10% reduction in number of plasma cells, at least about a 20% reduction in number of plasma cells, at least about a 30% reduction in number of plasma cells, at least about a 40% reduction in number of plasma cells, at least about a 50% reduction in number of plasma cells, at least about a 60% reduction in number of plasma cells, at least about a 70% reduction in number of plasma cells, at least about a 80% reduction in number of plasma cells, at least about a 90% reduction in number of plasma cells, at least about a 95% reduction in number of plasma cells, or at least about a 99% reduction in number of plasma cells. 17. The method of claim 1 , wherein said time is at least once per week for at least one week in a two month period. 18. The method of claim 17, wherein said time is at least once per week for at least two weeks in a two month period. 19. The method of claim 17, wherein said time is at least five days per week for at least one week in a two month period. 20. The method of claim 1 , wherein said dosage is at least about 500 to 2500 mg/m2. 21. The method of claim 1 , wherein said nucleoside analog drug is administered intravenously. 22. The method of claim 1 , wherein said nucleoside analog drug is administered orally. 23. The method of claim 5, wherein said administration of nucleoside analog drug ameliorates or prevents a symptom or condition associated with myeloma. 24. The method of claim 23, wherein said symptom or condition is selected from the group consisting of hypercalcemia, osteoporosis, osteolytic bone lesions, bone pain, unexplained bone fractures, anemia, renal damage, amyloidosis, diffuse chronic infection, weight loss, nausea, loss of appetite, and mental confusion. 25. The methods of claims 1-24, wherein said subject is a mammal. 26. The method of claim 25, wherein said mammal is a human. 27. A method of predicting efficacy of a nucleoside analog drug in a patient suffering from a hematological malignancy prior to treatment, comprising: a) isolating cells from said patient; b) treating isolated cells with the nucleoside analog drug; and c) measuring phosphorylation of one or more proteins of MKK3 , MKK6, p38 MAP kinase, ERKl, ERK2, and Akt kinase, and downstream signaling molecules thereof, wherein a decrease in phosphorylation is indicative of a favorable clinical response to said nucleoside analog drug. 28. The method of claim 27, wherein said cells are plasma cells isolated from bone marrow. 29. The method of claim 27, wherein said nucleoside analog drug is 8 -amino- adenosine. 30. The method of claim 28, further comprising measuring a rate of cell proliferation of said plasma cells, wherein stabilization or reduction of said rate of cell proliferation of plasma cells is indicative that said patient will respond favorably to the nucleoside analog drug. 31. The method of claim 30, further comprising comparing said rate of cell proliferation of plasma cells to a rate of cell proliferation of normal isolated cells from bone marrow, wherein a decrease in cell proliferation of plasma cells compared to said normal cells is indicative that said patient will respond favorably to the nucleoside analog drag. 32. The method of claim 27, wherein said decrease in phosphorylation is at least about 10% less than phosphorylation of an identical protein not treated with a nucleoside analog drug, at least about 20% less than phosphorylation of an identical protein not treated with a nucleoside analog drug, at least about 30% less than phosphorylation of an identical protein not treated with a nucleoside analog drag, at least about 40% less than phosphorylation of an identical protein not treated with a nucleoside analog drug, at least about 50% less than phosphorylation of an identical protein not treated with a nucleoside analog drug, at least 60% less than phosphorylation of an identical protein not treated with a nucleoside analog drug, at least 70% less than phosphorylation of an identical protein not treated with a nucleoside analog drug, at least 80% less than phosphorylation of an identical protein not treated with a nucleoside analog drag, at least 90% less than phosphorylation of an identical protein not treated with a nucleoside analog drag, or at least 100% less than phosphorylation of an identical protein not treated with a nucleoside analog drag. 33. The method of claim 27, wherein said decrease in phosphorylation is not attributable to loss of endogenous ATP levels. 34. The method of claim 27, wherein said proteins do not undergo a change in protein levels. 35. The method of claim 27, further comprising measuring phosphatase activity of PP2A, wherein an increase in phosphatase activity of PP2A is indicative that said patient will respond favorably to said nucleoside analog drug. 36. The method of claim 27, further comprising measuring apoptosis of said plasma cells, wherein an increase in apoptosis is indicative that patient will respond favorably to said nucleoside analog drug. 37. The method of claim 26, further comprising detecting caspase activation, wherein caspase activation is indicative that said patient will respond favorably to said nucleoside analog drug. 38. A method of screening a compound for efficacy in treating multiple myeloma, comprising: a) treating myeloma cells with said compound; and b) measuring phosphorylation of one or more proteins of MKK3, MKK6, p38 MAP kinase, ERKl, ERK2, and Akt kinase, and downstream signaling molecules thereof. wherein a decrease in phosphorylation of said one or more proteins is indicative of an efficacious treatment for multiple myeloma. 39. The method of claim 38, further comprising measuring phosphatase activity of PP2A, wherein an increase in phosphatase activity is indicative of an efficacious treatment for multiple myeloma. 40. The method of claim 38, farther comprising measuring apoptosis of said myeloma cells, wherein an increase in apoptosis is indicative of an efficacious treatment for multiple myeloma. 41. The method of claim 38, farther comprising measuring cell proliferation of said myeloma cells, wherein a decrease in cell proliferation is indicative of an efficacious treatment for multiple myeloma. 42. The method of claim 38, farther comprising detecting caspase activation, wherein caspase activation is indicative of an efficacious treatment of multiple myeloma. 43. The method of claim 38, wherein said myeloma cells are multi-drug resistant myeloma cells. 44. The method of claim 38, wherein said myeloma cells are steroid-resistant myeloma cells. 45. A method of treating a subject diagnosed with a hematological malignancy, comprising administering a therapeutically effective amount of 8-amino-adenosine. 46. The method of claim 45, wherein the hematological malignancy is myeloma. 47. The method of claim 46, wherein said subject was in remission from said myeloma and relapsed. 48. The method of claim 46, wherein said myeloma is multi-drug resistant. 49. The method of claim 46, further comprising assaying Bence-Jones proteins in urine of said subject, wherein a reduction or absence of Bence-Jones proteins is indicative of an effective treatment of said myeloma. 50. The method of claim 49, wherein said reduction of Bence-Jones proteins is at least about a 10% reduction in measured Bence-Jones proteins, at least about a 20% reduction in measured Bence-Jones proteins, at least about a 30% reduction in measured Bence-Jones proteins, at least about a 40% reduction in measured Bence- Jones proteins, at least about a 50% reduction in measured Bence-Jones proteins, at least about a 60% reduction in measured Bence-Jones proteins, at least about a 70% reduction in measured Bence-Jones proteins, at least about an 80% reduction in measured Bence-Jones proteins, at least about a 90% reduction in measured Bence- Jones proteins, at least about a 95% reduction in measured Bence-Jones proteins, or at least about a 99% reduction in measured Bence-Jones proteins. 51. The method of claim 46, further comprising assaying serum proteins of said subject for M protein, wherein a reduction or absence of M protein is indicative of an effective treatment of myeloma. 52. The method of claim 51, wherein said reduction of M protein is at least about a 10% reduction in measured M protein levels, at least about a 20% reduction in measured M protein levels, at least about a 30% reduction in measured M protein levels, at least about a 40% reduction in measured M protein levels, at least about a 50% reduction in measured M protein levels, at least about a 60% reduction in measured M protein levels, at least about a 70% reduction in measured M protein levels, at least about an 80% reduction in measured M protein levels, at least about a 90% reduction in measured M protein levels, at least about a 95% reduction in measured M protein levels, or at least about a 99% reduction in measured M protein levels. 53. The method of claim 51, wherein the absence of M protein is determined by immuno fixation. 54. The method of claim 51 , wherein said serum proteins are assayed by serum electrophoresis. 55. The method of claim 46, further comprising performing a biopsy on bone marrow of said subject to confirm a reduction in number of plasma cells indicative of an effective treatment of myeloma. 56. The method of claim 55, wherein said biopsy shows at least about a 5% reduction in number of plasma cells, at least about a 10% reduction in numb er of plasma cells, at least about a 20% reduction in number of plasma cells, at least about a 30% reduction in number of plasma cells, at least about a 40% reduction in number of plasma cells, at least about a 50% reduction in number of plasma cells, at least about a 60% reduction in number of plasma cells, at least about a 70% reduction in number of plasma cells, at least about a 80% reduction in number of plasma cells, at least aboτit a 90% reduction in number of plasma cells, at least about a 95% reduction in number of plasma cells, or at least about a 99% reduction in number of plasma cells. 57. The method of claim 45, wherein said 8-amino-adenosine is administered to said subject at least once per week for at least one week in a two month period. 58. The method of claim 45, wherein said 8-amino-adenosine is administered to said subject at least once per week for at least two weeks in a two month period. 59. The method of claim 45, wherein said 8-amino-adenosine is administered to said subject at least five days per week for at least one week in a two month period. 60. The method of claim 45, wherein said 8-amino-adenosine administered to said subject dosage is at least about 500 to 2500 mg/m2. 61. The method of claim 45, wherein said nucleoside analog drug is administered intravenously. 62. The method of claim 45, wherein said nucleoside analog drug is administered orally. 63. The method of claim 46, wherein said administration of 8-amino-adenosine ameliorates or prevents a symptom or condition associated with myeloma. 64. The method of claim 63, wherein said symptom or condition is selected from the group consisting of hypercalcemia, osteoporosis, osteolytic bone lesions, bone pain, unexplained bone fractures, anemia, renal damage, amyloidosis, diffuse chronic infection, weight loss, nausea, loss of appetite, and mental confusion. 65. The methods of claims 45-64, wherein said subject is a mammal. 66. The method of claim 65, wherein said mammal is a human.
法律状态
(WO200653252) LEGAL DETAILS FOR WO2006053252  Actual or expected expiration date=2008-05-12    Legal state=DEAD    Status=LAPSED     Event publication date=2005-11-14  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2005041037  Application date=2005-11-14  Standardized application number=2005WO-US41037     Event publication date=2006-05-18  Event code=WO/A2  Event type=Examination events  International application published without international search report  Publication country=WO  Publication number=WO2006053252  Publication stage Code=A2  Publication date=2006-05-18  Standardized publication number=WO200653252     Event publication date=2006-05-18  Event code=WO/AL  Event indicator=Pos  Event type=Designated states  Designated countries for regional patents BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG    Event publication date=2006-05-18  Event code=WO/AK  Event indicator=Pos  Event type=Designated states  Designated states AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW    Event publication date=2006-07-27  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2006053252  Publication stage Code=A3  Publication date=2006-07-27  Standardized publication number=WO200653252     Event publication date=2008-05-12  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE AU2005304320  Actual or expected expiration date=2009-11-05    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=AU Corresponding appl: AU2005304320  Application date in the designated or member state=2005-11-14   Application number in the designated or member state=2005AU-0304320 Corresponding cc:  Designated or member state=AU Corresponding pat: AU2005304320  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2006-05-18   Publication number in the designated or member state=AU2005304320    Event publication date=2007-05-17  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=AU     Event publication date=2007-06-07  Event code=WO/WWP  Event indicator=Pos  Event type=Examination events  Wipo information: published in national office Corresponding cc:  Designated or member state=AU     Event publication date=2007-06-07  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=AU     Event publication date=2009-11-05  Event code=AU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE CA2596543  Actual or expected expiration date=2010-11-15    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2596543  Application date in the designated or member state=2005-11-14   Application number in the designated or member state=2005CA-2596543 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2596543  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2006-05-18   Publication number in the designated or member state=CA2596543    Event publication date=2007-05-10  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=CA     Event publication date=2010-11-15  Event code=CA/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE EP1814390  Actual or expected expiration date=2009-07-17    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=EP Corresponding appl: EP05820981  Application date in the designated or member state=2005-11-14   Application number in the designated or member state=2005EP-0820981 Corresponding cc:  Designated or member state=EP Corresponding pat: EP1814390  Publication stage code in the designated or member state=A2  Publication date in the designated or member state=2007-08-08   Publication number in the designated or member state=EP1814390    Event publication date=2006-12-06  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2007-06-08  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=EP     Event publication date=2007-08-08  Event code=WO/WWP  Event indicator=Pos  Event type=Examination events  Wipo information: published in national office Corresponding cc:  Designated or member state=EP     Event publication date=2009-08-26  Event code=EP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE JP2008519854  Actual or expected expiration date=2009-02-03    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2007541376  Application date in the designated or member state=2005-11-14   Application number in the designated or member state=2007JP-0541376 Corresponding cc:  Designated or member state=JP Corresponding pat: JP2008519854  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2008-06-12   Publication number in the designated or member state=JP2008519854    Event publication date=2007-05-11  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=JP     Event publication date=2009-02-03  Event code=JP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE NZ  Actual or expected expiration date=2025-11-14    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=NZ Corresponding appl: NZ555212    Event publication date=2007-05-17  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=NZ  LEGAL DETAILS FOR DESIGNATED STATE US2009082304  Actual or expected expiration date=2011-06-10    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=US Corresponding appl: US71912105  Application date in the designated or member state=2005-11-14   Application number in the designated or member state=2005US-11719121 Corresponding cc:  Designated or member state=US Corresponding pat: US2009082304  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2009-03-26   Publication number in the designated or member state=US20090082304    Event publication date=2007-05-11  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=US     Event publication date=2011-06-10  Event code=US/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=US
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部